Abstract
Patients with diabetes differ in how their diabetes responds to treatment. Some individuals can have a marked glycaemic response; others have a poor response. Some have adverse drug reactions (e.g. hypoglycaemia with sulphonylureas, or diarrhoea with metformin), others do not. Diabetes is one of the few disease areas (outside of cancer therapy) where pharmacogenetics is impacting on our understanding of drug mechanism, and on direct clinical care. In this review, we address the complexities of studying drug response in diabetes, and highlight key recent advances both within monogenic diabetes and common type 2 diabetes.
| Original language | English |
|---|---|
| Pages (from-to) | 158-172 |
| Number of pages | 15 |
| Journal | Frontiers in Diabetes |
| Volume | 23 |
| DOIs | |
| Publication status | Published - 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Fingerprint
Dive into the research topics of 'Genetics of Drug Response in Diabetes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver